Showing results (1111-1120 of 2,755) with videos related to
Sort By:
Pageof 276
Pharmacogenomics|February 12, 2009
Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an exampleArlene R Hughes, Cynthia H Brothers, Michael Mosteller, et al.Pharmacogenomics|February 12, 2009
Collaborative genome-wide association studies of diverse diseases: programs of the NHGRI's office of population genomicsTeri A ManolioPharmacogenomics|February 12, 2009
CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian populationPaola Borgiani, Cinzia Ciccacci, Vittorio Forte, et al.Pharmacogenomics|February 12, 2009
Common sequence variant in lipoprotein lipase gene conferring triglyceride response to fibrate treatmentKuo-Liong Chien, Yen-Lin Lin, Hui-Chin Wen, et al.Pharmacogenomics|February 12, 2009
Genetic susceptibility to schizophrenia: role of dopaminergic pathway gene polymorphismsMeenal Gupta, Chitra Chauhan, Pallav Bhatnagar, et al.Pharmacogenomics|February 12, 2009
Growth hormone dose in growth hormone-deficient adults is not associated with IGF-1 gene polymorphismsSilke Meyer, Stephan Schaefer, Diana Ivan, et al.Pharmacogenomics|February 12, 2009
ABCB1 polymorphisms and the concentrations of lopinavir and ritonavir in blood, semen and saliva of HIV-infected men under antiretroviral therapyRita de Cassia Estrela, Fabio S Ribeiro, Paulo F Barroso, et al.Pharmacogenomics|December 17, 2013
Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokineticsShuguang Chen, Pamela St Jean, Julie Borland, et al.Pharmacogenomics|December 17, 2013
Effect of CYP2D6 on risperidone pharmacokinetics and extrapyramidal symptoms in healthy volunteers: results from a pharmacogenetic clinical trialPatricia Gassó, Sergi Mas, Katerina Papagianni, et al.Pharmacogenomics|December 17, 2013
Association between CYP2D6 genotypes and the clinical outcomes of adjuvant tamoxifen for breast cancer: a meta-analysisJin-A Jung, Hyeong-Seok LimPageof 276